Protective Effects of Chaihu Shugan San (柴胡疏肝散) on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance

Wei-ning Jiang; Dan Li; Tao Jiang; Jiao Guo; Yan-fen Chen; Jie Wang; Yun Zhou; Chao-yan Yang; Chun-ping Tang

doi:10.1007/s11655-016-2252-4

Your Location：

Home >

Browse articles >

Protective Effects of Chaihu Shugan San (柴胡疏肝散) on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance

Updated：2021-08-27

- Protective Effects of Chaihu Shugan San (柴胡疏肝散) on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance
- Chinese Journal of Integrative Medicine Vol. 24, Issue 2, Pages: 125-132(2018)
- Affiliations：
  
  1. School of Chinese Material Medica, Guangdong Pharmaceutical University,Guangzhou,China
  2. Center of Laboratorial Animals, Guangdong Pharmaceutical University,Guangzhou,China
  3. Guangdong Traditional Chinese Medicine Key Laboratory for Metabolic Diseases,Guangzhou,China
- Author bio：
- Funds：
  
  Suppport by the National Natural Science Foundation of China (No. 30973913) and the Science Foundation of Science and Technology Bureau of Guangdong (No. 2008A030101005)
- DOI：10.1007/s11655-016-2252-4
  CLC：
- Published：2018，
  
  Published Online：10 May 2016，
Scan for full text
Jiang, Wn., Li, D., Jiang, T. et al. Protective Effects of Chaihu Shugan San (柴胡疏肝散) on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance., Chin. J. Integr. Med. 24, 125–132 (2018). https://doi.org/10.1007/s11655-016-2252-4

Wei-ning Jiang, Dan Li, Tao Jiang, et al. Protective Effects of Chaihu Shugan San (柴胡疏肝散) on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance. [J]. Chinese Journal of Integrative Medicine 24(2):125-132(2018)
Jiang, Wn., Li, D., Jiang, T. et al. Protective Effects of Chaihu Shugan San (柴胡疏肝散) on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance., Chin. J. Integr. Med. 24, 125–132 (2018). https://doi.org/10.1007/s11655-016-2252-4 DOI：

Wei-ning Jiang, Dan Li, Tao Jiang, et al. Protective Effects of Chaihu Shugan San (柴胡疏肝散) on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance. [J]. Chinese Journal of Integrative Medicine 24(2):125-132(2018) DOI： 10.1007/s11655-016-2252-4.

摘要

To investigate the protective effects of Chinese medicine formulation Chaihu Shugan San (柴胡疏肝散

CHSGS) on nonalcoholic fatty liver disease (NAFLD) in rats with insulin resistance (IR) and its molecular mechanisms. Male Sprague-Dawley rats were randomly divided into six groups: the control group

the model group

Dongbao Gantai group (东宝肝泰

DBGT

0.09 g methionine/kg)

CHSGS high-dose group (CHSG-H

12.6 g crude drug/kg)

CHSGS medium-dose group (CHSG-M

6.3 g crude drug/kg)

and CHSGS low-dose group (CHSG-L

3.15 g crude drug/kg). After establishing the NAFLD rat model and treatment for 8 weeks

total cholesterol (TC)

triglyceride (TG)

high-density lipoprotein cholesterol (HDL-C)

free fatty acid (FFA)

fasting blood glucose (FBG)

fasting insulin (FINS) contents in blood serum

and TC

TG contents in the hepatic homogenate were measured by an automatic biochemical analyzer

and a homeostasis model assessment was applied to assess the status of IR

insulin sensitivity index (ISI)

and homeostasis model assessment for insulin secretion (HOMA-IS). The expression levels of adiponectin and leptin mRNA in liver tissue were analyzed by reverse transcription polymerase chain reaction. Pathological changes of livers were observed by hematoxylin-eosin staining of paraffin section. Compared with the model group

the serum levels of TC

FFA

FBG

FINS

IRI

ISI

and the liver levels of TC and TG in CHSG-H

CHSG-M

CHSG-L groups showed significant declines (P<0.01 or P<0.05); the serum levels of HDL-C

HOMA-IS were significantly increased (P<0.01 or P<0.05); the expression of leptin mRNA was dramatically decreased and the expression of adiponectin mRNA was increased in the hepatic tissue (P<0.01 or P<0.05). The fatty deposition of liver cells could also be alleviated. CHSGS could up-regulate the expression of adiponectin mRNA and down-regulate the expression of leptin mRNA on the liver

suggesting the CHSGS had positive therapeutic effect on NAFLD in rats with IR.

Abstract

To investigate the protective effects of Chinese medicine formulation Chaihu Shugan San (柴胡疏肝散

CHSGS) on nonalcoholic fatty liver disease (NAFLD) in rats with insulin resistance (IR) and its molecular mechanisms. Male Sprague-Dawley rats were randomly divided into six groups: the control group

the model group

Dongbao Gantai group (东宝肝泰

DBGT

0.09 g methionine/kg)

CHSGS high-dose group (CHSG-H

12.6 g crude drug/kg)

CHSGS medium-dose group (CHSG-M

6.3 g crude drug/kg)

and CHSGS low-dose group (CHSG-L

3.15 g crude drug/kg). After establishing the NAFLD rat model and treatment for 8 weeks

total cholesterol (TC)

triglyceride (TG)

high-density lipoprotein cholesterol (HDL-C)

free fatty acid (FFA)

fasting blood glucose (FBG)

fasting insulin (FINS) contents in blood serum

and TC

TG contents in the hepatic homogenate were measured by an automatic biochemical analyzer

and a homeostasis model assessment was applied to assess the status of IR

insulin sensitivity index (ISI)

the serum levels of TC

FFA

FBG

FINS

IRI

ISI

and the liver levels of TC and TG in CHSG-H

CHSG-M

CHSG-L groups showed significant declines (P<0.01 or P<0.05); the serum levels of HDL-C

suggesting the CHSGS had positive therapeutic effect on NAFLD in rats with IR.

关键词

Chaihu Shugan Sannonalcoholic fatty liver diseaselipid metabolisminsulin resistanceadiponectinleptinChinese Medicine

Keywords

Chaihu Shugan Sannonalcoholic fatty liver diseaselipid metabolisminsulin resistanceadiponectinleptinChinese Medicine

references

Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 2012;35:873–874.

Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43 (2 Suppl 1):S99–S112.

Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–946.

Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 2013;417:80–84.

Li F, Yang WY, Liang R, Liu XL, Qu D. Understanding the role of the liver in adjusting stress reactions. J Beijing Univ Tradit Chin Med (Chin) 1998;21:20–23.

Li SQ, Su ZH, Peng JB, Zou ZM, Yu CY. In vitro and in vivo antioxidant effects and the possible relationship between the antidepression efficacy of traditional Chinese medicine formulation Chaihu Shugan San. Chin J Natural Med 2010;8:353–361.

Li D, Jiang T, Fan HQ, Liang WN, Xiong KZ, Tang CP. Influence of Chaihushugan San on lipid metabolism and liver function in nonalcoholic fatty liver rats. Pharmacol Clin Chin Materia Med (Chin) 2013;29:8–11.

Mili S, Luli D, Stimac D. Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J Gastroenterol 2014;20:9330–9337.

Kucera O, Cervinkova Z. Experimental models of nonalcoholic fatty liver disease in rats. World J Gastroenterol 2014;20:8364–8376.

Zhang ZP, You TT, Zou LY, Wu T, Wu Y, Cui L. Effect of a compound Danshen preparation in preventing long-term gastric lipid emulsion administration-induced nonalcoholic steatohepatitis in rats. J Southern Med Univ (Chin) 2008;28:1109–1113.

Yao HX, Guo J, Tang CP, Yang CY, Chen YF, Chen YF, et al. Liver hypolipidemic protection of Compound Zhenzhu Tiaozhi Capsula on nonalcoholic fatty liver disease in rats and its mechanism. Chin Tradit Herbal Drugs (Chin) 2011;42:2075–2076.

Zhang L. The observation of Chaihu Shugan San clinical effect on non-alcoholic fatty liver. Chin Med Modern Distance Educ (Chin) 2013;11:90–91.

Zhang YH, Zhou M, Chen SW. Pharmacological study on Dongbaogantai pill. Chin Community Doctors (Chin) 2010;27:17.

Su DM, Li J, Zhuge L, Li JX. Influences of Jianpi Shugan Fang on ADP and TNF-α in rats with non-alcoholic steatohepatitis. J Beijing Univ Tradit Chin Med (Chin) 2011;34:826–831.

Fan JG. Nonalcoholic fatty liver disease diagnosis and treatment guidelines (recension in 2010). Chin J Gastroenterol Hepatol (Chin) 2010;19:483–484.

Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487–1495.

Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martínez-Chantar ML. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol 2009;41:969–976.

Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med 2009;87:679–695.

Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002;35:898–904.

Lu LG, Zeng MD. The role of improving insulin resistant in the treatment and prevention of nonalcoholic fatty liver disease. Chin J Hepatol (Chin) 2003;11:113–114.

Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatol 2002;37:56–62.

Almonacid-Urrego CC, Sánchez-Campos S, Tuñón MJ, González-Gallego J. Non-alcoholic steatohepatitis: What can we learn from animal models? Current Med Chem 2012;19:1389–1404.

You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 2005;42:568–577.

Naderali EK, Brwon MJ, Pickavance LC, Wilding JP, Doyle PJ, Williams G. Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. Clin Sci 2001;101:499–506.

Procaccini C, Galgani M, De Rosa V, Carbone F, Rocca C, Ranucci G, et al. Leptin: the prototypic adipocytokine and its role in NAFLD. Curr Pharm Des 2010;16:1902–1912.

Huang XD, Fan Y, Zhang H, Carbone F, La Rocca C, Ranucci G, et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol 2008;14:2888–2893.

Sehattenberg JM, Wang Y, Czaja MJ, Rigoli RM, Czaja MJ. Hepatoeyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005;280:9887–9894.

Zhu WF, Zhao Y, Xu KM, Shi MJ, Chen LH. Action mechanism of Dongbaogantai tablet in the prevention and treatment of alcoholic fatty liver in rats. China Pharm (Chin) 2009;20:2179–2181.

Zhao CP, Sun XN, Yu JZ. A clinical study on treating fatty liver with Jiangzhi Yigan Powder and Dongbao Gantai Pill. J Chin Med (Chin) 2005;20:34–35.

Li J, Li P. 149 cases of clinical observation on treatment of fatty liver with Dongbaogantai and Zhibituo. Sichuan Med J (Chin) 2000;21:724.

Yan M. Medicine research of non-alcoholic fatty liver. Clin J Chin Med (Chin) 2012;3:118–120.

Ge HY, Chen B, Liu HL, Li HQ. Therapeutic effects of saikoside on alcoholic liver disease in rats. Chin J Gerontol (Chin) 2011;31:662–663.

Chen JM, Zhang SS, Guo QK, Peng B, Peng YY, Li FY, et al. Study on the curative effect and the protection mechanism of Paeoniflorin on nonalcoholic fatty liver rats. China J Tradit Chin Med Pharm 2013;28:1376–1381.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effects of Portulaca oleracea on insulin resistance in rats with type 2 diabetes mellitus

Liver-adipose tissue crosstalk: A key player in the pathogenesis of glucolipid metabolic disease

Potent therapeutic effects of Shouwu Jiangqi Decoction (首乌僵芪汤) on polycystic ovary syndrome with insulin resistance in rats

Therapeutic Role of Tangshenkang Granule (糖肾康颗粒) in Rat Model with Diabetic Nephropathy

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Related Author

No data

Related Institution

Institute of Integrated Traditional & Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

Guangdong Research Center of Metabolic Diseases of Integrated Western and Chinese Medicine, Guangdong Pharmaceutical University

Joint Laboratory between Guangdong and Hong Kong on Metabolic Disease, Guangdong Pharmaceutical University

State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong

Zhangjiagang Hospital of Chinese Medicine, Zhangjiagang

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰